Targeting the Androgen Receptor Splice Variant 7 in Castration Resistant Prostate Cancer
Abstract
Androgen Deprivation Therapy (ADT) remains the first-line treatment option for patients with advanced metastatic prostate cancer. However, despite initial responses to ADT, the majority of patients develop resistance to ADT and progress to castration resistant prostate cancer(CRPC). The mechanisms of resistance to ADT are poorly understood and remains an urgent unmet need in prostate cancer research. It has been hypothesized that AR splice variants play a causal role in conferring endocrine resistance in prostate cancer. ARv7 is the most frequently expressed AR splice variant in CRPC and is associated with poor prognosis and resistance to ADT. The overarching goal of this study is to further delineate the role and mechanisms governing ARv7 activity in CRPC. We hypothesize that the use of AR N-terminal disrupting inhibitors may target the ARv7 and demonstrate increased effectiveness in the treatment of CRPC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2021
- Accession Number
- AD1165714
Entities
People
- Irene Lee
Organizations
- Dana–Farber Cancer Institute